CORT, Aroon Indicator entered an Uptrend on Oct 23, 2020.

NASDAQ:CORT   Corcept Therapeutics Incorporated
Over the last three days, Tickeron A.I.dvisor has detected that CORT's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red line stays below 30, this is an indicator that the stock could be poised for a strong Uptrend. For traders, this could mean going long the stock or exploring call options in the next month. Tickeron A.I.dvisor backtested this indicator and found 262 similar cases, 223 of which were successful. Based on this data, the odds of success are 85%. Current price $17.78 crossed the resistance line at $17.81 and is trading between $17.81 resistance and $17.32 resistance lines. Throughout the month of 09/23/20 - 10/23/20, the price experienced a +5% Uptrend, while the week of 10/16/20 - 10/23/20 shows a -0.83% Downtrend.

Bullish Trend Analysis
The Stochastic Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

CORT moved above its 50-day Moving Average on September 02, 2020 date and that indicates a change from a downward trend to an upward trend.

The 10-day Moving Average for CORT crossed bullishly above the 50-day moving average on September 09, 2020. This indicates that the trend has shifted higher and could be considered a buy signal. Tickeron A.I. detected that in 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.

Following a +2.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where CORT advanced for three days, in 279 of 334 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.